William L. Slone

Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial

Paul Kim, Ana M. Sánchez, Taylor J.R. Penke et al. · The Lancet Infectious Diseases · 2024 · 67 citations

Antimicrobial Susceptibility, Antibiotics, Crispr-cas3-enhanced Bacteriophage Cocktail +12

Bone marrow microenvironment modulation of acute lymphoblastic leukemia phenotype

Blake S. Moses, William L. Slone, Patrick Thomas et al. · Experimental Hematology · 2015 · 38 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Malignant Blood Disorder +5

Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia

Blake S. Moses, Rebecca Evans, William L. Slone et al. · Molecular Cancer Research · 2016 · 38 citations · Full text

Modeling Chemotherapy Resistant Leukemia <em>In Vitro</em>

William L. Slone, Blake S. Moses, Rebecca Evans et al. · Journal of Visualized Experiments · 2016 · 15 citations · Full text

Hematological Malignancy, Tumor Biology, Medicine +14

BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy

William L. Slone, Blake S. Moses, Ian Hare et al. · Oncotarget · 2016 · 15 citations · Full text

Bcl6 Modulation, Hematological Malignancy, Bcl6 Expression +14